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Introduction 
 
The CALUX bioassay is a promising screening method for the detection of dioxin-like 
compounds. The observed good sensitivity, low number of false negative results as well as the 
good correlations with the GC-HRMS TEQ-values in case of feed and food analyses allow this 
method to climb in the first assessment methods’ scale1,2,3. The low amount of sample needed in 
addition to those lattest advantages suggest that the CALUX bioassay could be a good screening 
method for epidemiological studies. The Belgian epidemiological study concerning the possible 
effect of the dioxin incident on the body burden of the Belgian population was an opportunity to 
test this method in comparison to the gold reference one : the GC-HRMS.  
The first part of this abstract presents epidemiological parameters (sensibility, specificity,...) 
of the CALUX bioassay using CALUX TEQ-values as estimators of the TEQ-values of the 17 
PCDD/Fs. The second part examines epidemiological determinants observed for CALUX and GC-
HRMS TEQ-values. 
 
Methods and Materials 
 
Sample collection 
In 1998 and 2000, a total of 478 plasma samples from 239 donors were collected by the 
Belgian Red Cross to evaluate the impact of the dioxin crisis on the dioxin body burdens. Those 
samples, collected in polyethylene bags (PE), were directly frozen at -80°C after donation. In the 
beginning of 2002, plasma samples were thawed and divided in accordance with the 3 analyses to 
perform: 60-250 mL for the determination of 17 PCDD/Fs and 4 cPCBs by GC-HRMS, 60 mL for 
the TEQ-value obtained by CALUX bioassay and 60 mL for the determination of the 7 PCB 
markers. All aliquots were stored in PE tubes and kept at -20°C until analyses.  
In addition to the second donation, donors were asked to fill in a questionnaire on their 
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environmental exposure (working place, living place, proximity of an incinerator,…) and their 
dietary habits (frequency of consumption of meat, eggs, fish,…). More details on the studied 
population are presented by Debacker et al4. 
 
Chemical and bio-analyses 
The Center of Analysis of Residues in Traces (CART, Liège, Belgium) was in charge of the 
analyses of 17 PCDD/Fs and 4 non-ortho PCBs. After addition of a mixture of 13C-labelled 
standards, 40 mL of sample were mixed with formic acid and loaded on a Isolute C18 cartridge for 
extraction. The clean-up was performed on a Power-prep system using disposable silica, alumina 
and carbon columns. The purified extracts were then injected in a Helwett Packard 6890 series Gas 
Chromatography- Autospec Ultima High Resolution Mass Spectrometer5. Results were expressed 
in pg TEQ/g lipids using human WHO-TEF6. 
CALUX analyses were performed by the Belgian Scientific Institute of Public Health 
(Brussels, Belgium) using mouse hepatoma H1L6.1 cells from XDS Inc. (Durham, USA). After a 
liquid-liquid extraction on 10 mL of plasma sample, the extract was purified on an acid silica 
column in series with an activated carbon column. After elution from the silica column, the extract 
was fractionated on the carbon column to yield fractions containing PCDD/Fs on one hand (DX 
fraction) and PCBs on the other hand (PCB fraction). Only the DX fraction was used for the 
determination of AhR activity. Measurements were performed using a Lucy 1 luminometer from 
Anthos Labtec (Salzburg, Austria). Results were expressed in pg TEQ/g lipids7.  
 
Results and Discussion 
 
Epidemiological parameters of CALUX bioassay as a screening for the 17 PCDD/Fs’ TEQ-value 
Results obtained for the validation of plasma analyses by CALUX bioassay were already 
reported7,8. In these previous papers, preliminary TEQ-values obtained for plasma by CALUX and 
GC-HRMS were plotted in order to compare and explain differences between the two methods. 
Now that all plasma samples of the study have been analysed, it is possible to present final results 
and calculate the characteristics of the CALUX bioassay as a screening for biological samples. To 
avoid underestimation of the GC-HRMS TEQ-values due to congeners under the limits of 
quantification, the concentrations of those congeners were estimated using an extrapolation based 
on the concentration of one other congener. This last was chosen on account of its concentration in 
the sample (above its LOQ) and the correlation observed with the non-quantifiable congener. By 
this way, the TEQ-value for GC-HRMS is closer to the real concentration than by applying 
correction with lower bound or upper bound values.  
 
Choice of the data set: Among the 478 samples analyzed, 18 were not reported because of troubles 
during the lipid determination, the bio- or the chemical analyses. Moreover, 5 samples were 
considered as outliers in the comparison graph, and thus discarded for further calculations. Because 
each donor has given two samples of plasma, three separate correlation graphs were made to detect 
any discrepancy between samples of 1998 and 2000. A summary of the results obtained for the 
regression of CALUX TEQ-values in function of GC-HRMS TEQ-value for the 17 PCDD/F 
congeners is presented in Table 1. For those 3 data sets, the slope values are the same. Only small 
variations in the intercept values are observed and are mainly due to the extreme points of the 
graphs which differ in 1998 and 2000.  
Mean and median concentrations are quite similar for samples of 1998 compared to those of 2000 
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TEQ-values are higher than GC-HRMS TEQ values. The presence of other AhR ligands in the DX 
fraction obtained for the bioassay is probably the major explanation of this difference. 
 
Table 1: Regression equations obtained for CALUX TEQ-values as a function of GC-HRMS TEQ-
values considering samples of 1998, 2000 or 1998 and 2000 (CALUX TEQ= b0 + b1 GC-
HRMS TEQ) 
 
Year of collection Number of samples b0 b1 R² R p-value 
1998 228 18.23 0.74 0.34 0.58 <0.0001 
2000 227 16.10 0.74 0.33 0.57 <0.0001 




Table 2: Mean and median concentrations (pg TEQ/g lipids) observed by CALUX and GC-HRMS 
for samples collected in 1998 and in 2000 
 
CALUX analysis (pg TEQ/g lip) GC-HRMS analysis (pg TEQ/g lip) Year of 
collection Mean Median SD Range Mean Median SD Range 
1998 38.1 35.6 17.8 2.8 – 103.0 26.7 25.2 14.0 0.3 – 93.2 
2000 36.4 32.6 18.9 5.1 – 101.0 26.9 23.6 14.3 2.0 – 74.0 
 
Sensibility and specificity of CALUX bioassay for plasma analyses: As observed in Tables 1 and 2, 
the difference between samples of 1998 and 2000 is minimal. For this reason, the 2 sets of samples 
were used for calculation of the sensibility and the specificity. To obtain curves of these two 
characteristics, the specificity and the sensibility were determined at different GC-HRMS TEQ-
values as threshold limits (L). For each fixed limit, the number of samples showing CALUX and 
GC-HRMS TEQ-values above L (a), CALUX and GC-HRMS TEQ-values below L (d), CALUX 
TEQ-value higher than L with a GC-HRMS TEQ-concentration lower than L (b) as well as the 
number of samples in the opposite situation (c) were counted (Table 3). By definition, the 
sensibility at a threshold limit is the proportion of samples with CALUX and GC-HRMS TEQ-
values above L on the number of samples with GC-HRMS TEQ-concentration higher than L, or a / 
(a + c). In opposition, the specificity at a fixed threshold limit is the proportion of samples with 
CALUX and GC-HRMS TEQ-values below L on the number of samples with GC-HRMS TEQ-
concentration under the limit, or d / (d + b). 
 
Table 3: Calculation of the sensibility and the specificity for the fixed limit L: 
sensibility = a / (a + c), specificity = d / (d + b) 
 
  GC-HRMS 
  TEQ value > L TEQ value < L 
TEQ value > L a b   
CALUX 
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Figure 1 presents the curves of sensibility and specificity of CALUX bioassay in function of the 
GC-HRMS TEQ-concentration. In the case of plasma samples, the sensibility ranges from 68.4% to 
99.4% and is the highest at low TEQ-concentrations. The specificity varies from 9.1% to 91.7% 
and raises as the GC-HRMS TEQ-value increases. These observations are in accordance with the 
regression equation presented before. The intercept value of 17.18 pg TEQ/g lipids shows clearly 
that the CALUX bioassay overestimates the GC-HRMS results at low contamination levels. In 
addition to this positive intercept, the slope value of 0.74 indicates that the differences between 
CALUX and GC-HRMS TEQ-values tend to decrease as PCDD/Fs concentration increases. Until 
now, no clear explanation for this higher discrepancy between the two methods at low levels of 
contamination was found.  
For PCDD/Fs concentrations between 40 and 45 pg TEQ/g lip, the CALUX bioassay presents 
similarities in the percentage of sensibility and specificity, namely 75%. Below those 
concentrations, the sensibility improves while the specificity drops rapidly. At higher 
concentrations, the sensibility stays more or less constant and the specificity continues to rise. It 
seems that the CALUX bioassay gives a better estimation of the 17 PCDD/Fs’ toxicity for samples 
with concentrations higher than 40 pg TEQ/g lipids. However, calculations of specificity and 
sensibility at those high concentrations are based on a small number of data, since 77% of samples 
have TEQ-values under 40 pg TEQ/g lipids. Analyses by CALUX bioassay of a highly 
contaminated population could be interesting in order to improve the reliability of the present 
results.  
Despite the loss of specificity at lower PCDD/Fs contamination levels, the observed good 
correlation between GC-HRMS and CALUX on the whole range of concentrations suggests that 
this bioassay could be used as a screening tool to distinguish a more contaminated population from 
a control population. This use was already demonstrated by Kayama and coworkers9. In this 
previous study, CALUX analyses have detected a Japanese district where female farmers presented 
higher TEQ-values. In this perspective, the GC-HRMS analyses would then be useful to identify 
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Figure 1: Curves of specificity and sensibility for CALUX bioassay in function of the GC-HRMS 
TEQ concentrations of the 17 PCDD/F (pg TEQ/g lip) as decision threshold. 
 
Percentage of false positives and false negatives: As previously described, the CALUX TEQ-value 
reflects the toxicity of all the AhR ligands present in the DX fraction, including their synergistic, 
additive and antagonistic effects on the Ah receptor.  For this reason, it seems normal to obtain 
different TEQ-value than the GC-HRMS, which is based on the additive principle of toxicity. For 
the present study, only 20% of the samples had a CALUX TEQ-value below the GC-HRMS result. 
For most plasma samples, the CALUX bioassay gave a TEQ-value equal or higher than the toxicity 
of the 17 PCDD/Fs detected by GC-HRMS. In the case of blood, there is no norm on the PCDD/F 
content of samples. Therefore, it seems difficult and inappropriate to calculate false positive and 
false negative rates.  
 
 
Cost comparison: The major advantages of CALUX bioassay is its price and the low amount of 
samples needed for one analysis. It is therefore less constraining for the sampling and the storage of 
samples. Moreover, for the same price, 2.5 times more analyses can be performed by CALUX. The 
time needed for analysis is the same for both methods in perfect conditions. However, technical 
problems with highly sensitive instruments like GC-HRMS cannot be neglected and will probably 
increase the 18 weeks foreseen for 500 analyses.  
 
Table 4: Comparisons of price, time and amount of sample needed for the CALUX and the GC-
HRMS analyses 
 
 Price/analysis Number of 
analyses/week 
Amount of sample 
for 1 analyse 
Price for 500 
analyses 
Number of weeks needed 
for the 500 analyses 
CALUX 250 € 30 10 - 20 mL 125 000 € 18  
GC-HRMS 625 € 30 10*- 40 mL 312 500 € 18  
* Validation in progress 
 
Available information: The GC-HRMS analysis is without any doubt more selective than the 
CALUX bioassay. It allows the determination of the contamination source on the basis of the 
observed profile of PCDDs and PCDFs. The CALUX bioassay gives a global TEQ-value of all the 
dioxin-like compounds present in the final extract, including the 17 PCDD/Fs and other AhR 
ligands. This permits contamination events caused by other dioxin-like compounds than PCDD/Fs, 
such as brominated dioxins or furans, to be detected by CALUX bioassay. For these reason, the two 
methods can be considered as complementary.  
 
Epidemiological determinants of the CALUX and GC-HRMS TEQ-values 
Knowing that CALUX presents a TEQ-value that is different but dependent on the TEQ-value 
obtained by GC-HRMS, some questions can be raised concerning the use for epidemiological 
study: What are the epidemiological factors that explain the TEQ-values of the two methods? Are 
they similar? Do the other AhR ligands have enough importance on the CALUX TEQ results to 
cover up determinants of the 17 PCDD/F congeners or are they going to introduce new 
determinants in the model for CALUX compared to GC-HRMS results?  
To answer these questions, TEQ-values obtained by CALUX and GC-HRMS for samples collected 
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collected through the questionnaire. All statistical treatments were performed on the logarithm of 
TEQ-values, using SAS® system for windows (8th edition).  
After single regression performed on GC-HRMS TEQ-values, 6 factors were found to be 
significant determinants for the chemical TEQ results obtained for plasma samples: the age of 
donors (p<0.0001, R²=0.23), the number of years that donors have lived in their actual city 
(p=0.001, R²=0.05), the intake of medicine (p=0.004, R²=0.04), the consumption of soft drink 
(p=0.005, R²=0.04), the body mass index (p=0.03, R²=0.02) and the smoking habit (p=0.03, 
R²=0.02). However, the introduction of those factors in the multiple regression analysis showed 
that most of these were dependent on the age of donors. Indeed multiple regression revealed that 
only the age of donors (p<0.0001) and the consumption of dairy products (p=0.03) correlated 
significantly with the TEQ-values of the 17 PCDD/Fs.  
For CALUX TEQ-values single regression also revealed a significant effect for 4 of the 6 factors 
that were significant for the GC-HRMS values: the age of donors (p<0.0001, R²=0.10), the 
consumption of soft drink (p=0.009, R²=0.03), the intake of medicine (p=0.01, R²=0.03) and the 
smoking habits (p=0.03, R²=0.02). The two other factors found to be significant for GC-HRMS 
TEQ-values presented p-values between 0.05 and 0.06. Analogously, the introduction of all the 
possible determinants in multiple regression analysis reduced the model to only two factors: the age 
of donors (p<0.0001) and the consumption of full-cream milk (p=0.03). In this case, the smoking 
habit was nearly significant, with higher CALUX TEQ-values for non smokers. 
Comparison of the determinants of the two methods seems to indicate that the donor’s age is the 
most important determining factor for both TEQ-results. The coefficient of determination of 0.10 
observed for this factor on the CALUX TEQ-value is similar to the one previously reported by 
Kayama and coworkers with the same CALUX bioassay9. More surprising is the significant 
correlation of one specific dairy product for CALUX bioassay compared to GC-HRMS. This 
difference may be due to analytical deviations for some samples. When considering the total dairy 
consumption (milk, cheese, butter,…) instead of the full-cream milk consumption solely for the 
multiple regression analysis of CALUX, the dairy products are nearly a significant determinant 
(p=0.057). In any way, whatever the analytical method used, these results seem to indicate that 
dairy products are the major sources of PCDD/Fs in the Belgian population. No correlation with the 
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